{
    "ticker": "ORKT",
    "name": "Orchard Therapeutics plc",
    "description": "Orchard Therapeutics plc is a biotechnology company focused on the development and commercialization of innovative gene therapies for patients with serious and life-threatening genetic disorders. Founded in 2015, Orchard aims to transform the treatment landscape for rare diseases by harnessing the power of gene therapy to provide potentially curative options for patients. The company is headquartered in London, UK, and has built a robust pipeline of gene therapies targeting various conditions, including metachromatic leukodystrophy (MLD) and beta-thalassemia. Orchard's lead product candidate, OTL-200, is designed to treat MLD, a rare inherited disorder that affects the nervous system and leads to severe disability. The company is committed to advancing science and improving patient outcomes through its innovative therapies and has established collaborations with leading academic institutions and industry partners. Orchard Therapeutics continues to seek regulatory approval for its therapies while also investing in research to expand its pipeline and address additional genetic disorders. Through its pioneering work, Orchard is dedicated to providing hope for patients and families affected by rare genetic diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "London, United Kingdom",
    "founded": "2015",
    "website": "https://www.orchardtherapeutics.com",
    "ceo": "Mark Rothera",
    "social_media": {
        "twitter": "https://twitter.com/orchardtx",
        "linkedin": "https://www.linkedin.com/company/orchard-therapeutics/"
    },
    "investor_relations": "https://investors.orchardtherapeutics.com",
    "key_executives": [
        {
            "name": "Mark Rothera",
            "position": "CEO"
        },
        {
            "name": "Katherine A. Kahn",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "OTL-200",
                "OTL-103"
            ]
        }
    ],
    "seo": {
        "meta_title": "Orchard Therapeutics plc | Gene Therapies for Rare Genetic Disorders",
        "meta_description": "Explore Orchard Therapeutics plc, a biotechnology company focused on innovative gene therapies for rare genetic disorders. Learn about our pipeline and commitment to patient care.",
        "keywords": [
            "Orchard Therapeutics",
            "Gene Therapy",
            "Rare Diseases",
            "Biotechnology",
            "OTL-200",
            "OTL-103"
        ]
    },
    "faq": [
        {
            "question": "What is Orchard Therapeutics known for?",
            "answer": "Orchard Therapeutics is known for developing innovative gene therapies for patients with rare genetic disorders."
        },
        {
            "question": "Who is the CEO of Orchard Therapeutics?",
            "answer": "Mark Rothera is the CEO of Orchard Therapeutics plc."
        },
        {
            "question": "Where is Orchard Therapeutics headquartered?",
            "answer": "Orchard Therapeutics is headquartered in London, United Kingdom."
        },
        {
            "question": "What are Orchard's main products?",
            "answer": "Orchard's main products include OTL-200 and OTL-103, gene therapies targeting specific genetic disorders."
        },
        {
            "question": "When was Orchard Therapeutics founded?",
            "answer": "Orchard Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "SGMO",
        "NVTA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}